DK0743304T3 - 4-(Arylaminomethylen)-2,4-dihydro-pyrazol-3-oner - Google Patents

4-(Arylaminomethylen)-2,4-dihydro-pyrazol-3-oner

Info

Publication number
DK0743304T3
DK0743304T3 DK96107518T DK96107518T DK0743304T3 DK 0743304 T3 DK0743304 T3 DK 0743304T3 DK 96107518 T DK96107518 T DK 96107518T DK 96107518 T DK96107518 T DK 96107518T DK 0743304 T3 DK0743304 T3 DK 0743304T3
Authority
DK
Denmark
Prior art keywords
opt
substd
alkyl
so2nr4r5
so2a
Prior art date
Application number
DK96107518T
Other languages
Danish (da)
English (en)
Inventor
Michael Dr Arlt
Rochus Dr Jonas
Maria Christadler
Guenter Schneider
Michael Dr Klockow
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK0743304T3 publication Critical patent/DK0743304T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK96107518T 1995-05-17 1996-05-10 4-(Arylaminomethylen)-2,4-dihydro-pyrazol-3-oner DK0743304T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19518082A DE19518082A1 (de) 1995-05-17 1995-05-17 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one

Publications (1)

Publication Number Publication Date
DK0743304T3 true DK0743304T3 (da) 2003-07-14

Family

ID=7762136

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96107518T DK0743304T3 (da) 1995-05-17 1996-05-10 4-(Arylaminomethylen)-2,4-dihydro-pyrazol-3-oner

Country Status (22)

Country Link
US (1) US5869516A (fr)
EP (1) EP0743304B1 (fr)
JP (1) JP3996656B2 (fr)
KR (1) KR100413154B1 (fr)
CN (1) CN1066138C (fr)
AT (1) ATE235469T1 (fr)
AU (1) AU713042B2 (fr)
CA (1) CA2176649C (fr)
CZ (1) CZ291572B6 (fr)
DE (2) DE19518082A1 (fr)
DK (1) DK0743304T3 (fr)
ES (1) ES2192588T3 (fr)
HU (1) HUP9601328A3 (fr)
NO (1) NO306777B1 (fr)
PL (1) PL186049B1 (fr)
PT (1) PT743304E (fr)
RU (1) RU2180659C2 (fr)
SI (1) SI0743304T1 (fr)
SK (1) SK284295B6 (fr)
TW (1) TW349093B (fr)
UA (1) UA59330C2 (fr)
ZA (1) ZA963918B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
DE19642284A1 (de) * 1996-10-14 1998-04-16 Merck Patent Gmbh Pyrazolinone zur Behandlung von Potenzstörungen
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (fr) 1997-05-30 2002-08-20 Cell Pathways, Inc. Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
DE19807423A1 (de) 1998-02-21 1999-08-26 Hoechst Marion Roussel De Gmbh Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
KR20060005375A (ko) * 2003-04-18 2006-01-17 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제로서의 피라졸 유도체
JP2008516964A (ja) * 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
BRPI0606132A2 (pt) * 2005-10-12 2009-06-02 Sicor Inc formas cristalinas de docetaxel e processos para seu preparo
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1956906A4 (fr) 2005-11-09 2009-12-30 Combinatorx Inc Procedes, compositions et kits pour le traitement de pathologies
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (fr) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008095136A2 (fr) 2007-01-31 2008-08-07 Henkin Robert I Procédés de détection de substances biologiques
EP2002835A1 (fr) 2007-06-04 2008-12-17 GenKyo Tex Dérivés de pyrazolo pyridine en tant qu'inhibiteurs de la NADPH oxydase
EP2000176A1 (fr) * 2007-06-04 2008-12-10 GenKyo Tex Dérivés de tétrahydroindole en tant qu'inhibiteurs d'oxydase NADPH
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2166009A1 (fr) * 2008-09-23 2010-03-24 Genkyo Tex Sa Dérivés de pyridine pyrazolo en tant qu'inhibiteurs d'oxydase NADPH
EP2166008A1 (fr) * 2008-09-23 2010-03-24 Genkyo Tex Sa Dérivés de pyridine pyrazolo en tant qu'inhibiteurs d'oxydase NADPH
EP2165707A1 (fr) * 2008-09-23 2010-03-24 Genkyo Tex Sa Dérivés de pyrazolo pyridine en tant qu'inhibiteurs de la NADPH oxydase
EP2166010A1 (fr) 2008-09-23 2010-03-24 Genkyo Tex Sa Dérivés de pyridine pyrazolo en tant qu'inhibiteurs d'oxydase NADPH
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2305679A1 (fr) 2009-09-28 2011-04-06 GenKyoTex SA Dérivés de pyrazoline dione en tant qu'inhibiteurs d'oxydase NADPH
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014055801A1 (fr) 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
BR112016017781A2 (pt) 2014-02-14 2017-08-08 Inception 2 Inc Compostos de pirazolona e usos dos mesmos
EP3108245B1 (fr) 2014-02-18 2020-07-22 Robert I. Henkin Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
EP3479843A1 (fr) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Utilisation d'inhibiteurs de nox pour le traitement du cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905997A (en) * 1974-06-21 1975-09-16 Warner Lambert Co 3-Aryl-5-oxo-2-pyrazoline-4-carboxanilides and process therefor
US4355159A (en) * 1979-05-23 1982-10-19 Ciba-Geigy Corporation Nickel complex pigments of azines
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
DK169672B1 (da) * 1985-05-20 1995-01-09 Mitsubishi Chem Ind Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater
US5162528A (en) * 1986-12-17 1992-11-10 Bayer Aktiengesellschaft Herbicidal and fungicidal agents based on substituted pyrazolin-5-one derivatives
DE3728278A1 (de) * 1986-12-17 1988-06-23 Bayer Ag Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
DE4130833A1 (de) * 1991-09-17 1993-03-18 Bayer Ag Diarylpyrazolinone
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one

Also Published As

Publication number Publication date
CZ142196A3 (en) 1997-01-15
AU713042B2 (en) 1999-11-25
CZ291572B6 (cs) 2003-04-16
NO961996L (no) 1996-11-18
HUP9601328A2 (en) 1997-02-28
ZA963918B (en) 1996-11-25
SK58996A3 (en) 1996-12-04
SI0743304T1 (en) 2003-10-31
CN1141291A (zh) 1997-01-29
JP3996656B2 (ja) 2007-10-24
RU2180659C2 (ru) 2002-03-20
NO306777B1 (no) 1999-12-20
KR100413154B1 (ko) 2004-05-12
JPH08311035A (ja) 1996-11-26
PT743304E (pt) 2003-08-29
AU5225396A (en) 1996-11-28
NO961996D0 (no) 1996-05-15
DE59610254D1 (de) 2003-04-30
CA2176649A1 (fr) 1996-11-18
SK284295B6 (sk) 2005-01-03
US5869516A (en) 1999-02-09
DE19518082A1 (de) 1996-11-21
ATE235469T1 (de) 2003-04-15
PL186049B1 (pl) 2003-09-30
HUP9601328A3 (en) 1999-04-28
HU9601328D0 (en) 1996-07-29
KR960041166A (ko) 1996-12-19
ES2192588T3 (es) 2003-10-16
UA59330C2 (uk) 2003-09-15
EP0743304B1 (fr) 2003-03-26
EP0743304A1 (fr) 1996-11-20
CA2176649C (fr) 2008-08-05
PL314286A1 (en) 1996-11-25
TW349093B (en) 1999-01-01
CN1066138C (zh) 2001-05-23

Similar Documents

Publication Publication Date Title
DK0743304T3 (da) 4-(Arylaminomethylen)-2,4-dihydro-pyrazol-3-oner
ES2116801T3 (es) Empleo de derivados de adamantano para el tratamiento de tinnitus.
AU5271093A (en) Dyeing compositions for keratinous fibres based on para- phenylenediamines, meta-phenylenediamines and benzimidazole derivatives, and dyeing process employing them
LU90371I2 (fr) Coaprovel-Irbesartan/hydrochlorothiazide
DK0465339T3 (da) Fremgangsmåde til farvning af keratinfibre med 4-hydroxyindolderivater ved sur pH-værdi og midler til anvendelse ved fremgangsmåden
DE69509753D1 (de) Hetero aromatische oxazole und deren verwendung
AU4929690A (en) Phenyl pyradazine-3(2H)one, thiadizin-2(3H)one, triazin-3(2H) one and oxadiazin-5(4H)one derivatives for the treatment of congestive heart failure
FI923540A (fi) Arylalkylaminer och -amider med antikonvulsiva och nervskyddande egenskaper.
DK0737678T3 (da) 4-Indolylpiperazinyl-derivater
NO961404L (no) 4-indolylpiperazinyl-derivater
DK0690845T3 (da) Piperazinderivater som 5-HT1A-ligander
RS50136B (sr) Derivati tiazolidindiona i njihova upotreba kao antidijabetika
DE3775795D1 (de) N-aryltetrahydrophthalimidderivate und deren vorprodukte.
DK0758648T3 (da) Substituerede 4H-pyraner med en modulerende virkning på kaliumkanaler
TR199501278A2 (tr) Alkil-5-metilsülfonil-benzoilguanidin türevleri.
NO963854D0 (no) Okulart spenningsnedsettende middel
ATE154601T1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten